{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Biktarvy+Tab&page=2", "query": { "intervention": "Biktarvy Tab", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Biktarvy+Tab&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-28T04:39:16.267Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02603107", "title": "Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "RTV", "type": "DRUG" }, { "name": "ATV", "type": "DRUG" }, { "name": "DRV", "type": "DRUG" }, { "name": "COBI", "type": "DRUG" }, { "name": "ATV/co", "type": "DRUG" }, { "name": "DRV/co", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "ABC/3TC", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 578, "start_date": "2015-11-20", "completion_date": "2019-12-23", "has_results": true, "last_update_posted_date": "2020-12-29", "last_synced_at": "2026-09-28T04:39:16.267Z", "location_count": 63, "location_summary": "Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 49 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02603107" }, { "nct_id": "NCT06891066", "title": "A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Human Immunodeficiency Virus Type 1 (HIV-1) Infection" ], "interventions": [ { "name": "ISL", "type": "DRUG" }, { "name": "ULO", "type": "DRUG" }, { "name": "BIC/FTC/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2025-04-14", "completion_date": "2031-09-30", "has_results": false, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-09-28T04:39:16.267Z", "location_count": 11, "location_summary": "San Francisco, California • West Hollywood, California • Washington D.C., District of Columbia + 8 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06891066" }, { "nct_id": "NCT03797014", "title": "B/F/TAF Switch Study for HIV-HBV Coinfection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV-1-infection", "Hepatitis B" ], "interventions": [ { "name": "B/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2019-04-30", "completion_date": "2023-05-05", "has_results": true, "last_update_posted_date": "2023-11-03", "last_synced_at": "2026-09-28T04:39:16.267Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Philadelphia, Pennsylvania", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03797014" }, { "nct_id": "NCT06613685", "title": "Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "lepetegravir", "type": "DRUG" }, { "name": "lenacapavir pacfosacil", "type": "DRUG" }, { "name": "Bictegravir/emtricitabine/tenofovir alafenamide", "type": "DRUG" }, { "name": "lepetegravir/lenacapavir pacfosacil FDC", "type": "DRUG" }, { "name": "Placebo to Match BVY", "type": "DRUG" }, { "name": "Placebo to Match GS1720/GS-4182 FDC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 73, "start_date": "2024-10-21", "completion_date": "2026-03-16", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-09-28T04:39:16.267Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Torrance, California • West Hollywood, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Torrance", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "DeLand", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06613685" }, { "nct_id": "NCT04826562", "title": "Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Human Immunodeficiency Virus" ], "interventions": [ { "name": "Dolutegravir/Lamivudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Saint Michael's Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2021-09-26", "completion_date": "2023-12-30", "has_results": false, "last_update_posted_date": "2023-10-11", "last_synced_at": "2026-09-28T04:39:16.267Z", "location_count": 1, "location_summary": "Newark, New Jersey", "locations": [ { "city": "Newark", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04826562" }, { "nct_id": "NCT04650269", "title": "Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Harm Reduction", "HIV Infections", "Drug Use" ], "interventions": [ { "name": "Biktarvy 50Mg-200Mg-25Mg Tablet", "type": "DRUG" }, { "name": "HIV care", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2021-03-04", "completion_date": "2023-12-31", "has_results": true, "last_update_posted_date": "2025-01-08", "last_synced_at": "2026-09-28T04:39:16.267Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04650269" }, { "nct_id": "NCT07645287", "title": "A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "GS-3242 Tablet", "type": "DRUG" }, { "name": "GS-3242 Injection", "type": "DRUG" }, { "name": "Lenacapavir Tablet", "type": "DRUG" }, { "name": "Lenacapavir Injection", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 175, "start_date": "2026-06-15", "completion_date": "2033-04", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-09-28T04:39:16.267Z", "location_count": 45, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 40 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07645287" }, { "nct_id": "NCT05457530", "title": "Doravirine and Weight Gain in Antiretroviral Naive", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Body Weight Changes", "Human Immunodeficiency Virus", "ART", "Obesity", "Minority Health", "BMD", "Metabolic Syndrome", "Fasting" ], "interventions": [ { "name": "DOR/3TC/TDF", "type": "DRUG" }, { "name": "DOR + FTC/TAF", "type": "COMBINATION_PRODUCT" }, { "name": "BIC/FTC/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Prism Health North Texas", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2022-08-01", "completion_date": "2023-05-03", "has_results": false, "last_update_posted_date": "2023-05-12", "last_synced_at": "2026-09-28T04:39:16.267Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05457530" }, { "nct_id": "NCT03348163", "title": "(mo)BETTA Trial in Transwomen for Optimization of ART", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "B/FTC/TAF", "type": "DRUG" }, { "name": "Current ART", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center, Houston", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 26, "start_date": "2018-06-06", "completion_date": "2020-12-15", "has_results": true, "last_update_posted_date": "2022-10-03", "last_synced_at": "2026-09-28T04:39:16.267Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03348163" }, { "nct_id": "NCT04564547", "title": "Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "Islatravir", "type": "DRUG" }, { "name": "Ulonivirine", "type": "DRUG" }, { "name": "BIC/FTC/TAF", "type": "DRUG" }, { "name": "Placebo to ISL", "type": "DRUG" }, { "name": "Placebo to Ulonivirine", "type": "DRUG" }, { "name": "Placebo to BIC/FTC/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 161, "start_date": "2021-03-09", "completion_date": "2025-01-30", "has_results": true, "last_update_posted_date": "2026-01-26", "last_synced_at": "2026-09-28T04:39:16.267Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Los Angeles, California • Ft. Pierce, Florida + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Decatur", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04564547" } ] }